Navigation Links
Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide
Date:5/12/2009

- Data to be presented at Digestive Disease Week 2009 -

CAMBRIDGE, Mass. and NEW YORK, May 12, 2009 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be reporting additional clinical data from their Phase 2b studies for linaclotide, a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC), during the 2009 Digestive Disease Week (DDW) annual meeting being held in Chicago, IL from May 30 through June 4, 2009. The presentations will include three oral and one poster presentation. Ironwood and Forest presented the initial analyses from both the IBS-C and CC studies last year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

The scheduled times and titles of the presentations are:

  • Effect of Linaclotide on IBS-C Symptoms in the First Week of Treatment: Results from a Phase 2b Study, an oral presentation by Anthony Lembo, M.D. on Sunday, May 31 at 10:45 a.m.
  • Global Endpoints in IBS Clinical Trials: Results from a Phase 2b Study of Linaclotide, an oral presentation by Jeffrey Johnston, M.D., F.A.C.P., F.A.C.G. on Sunday, May 31 at 2:30 p.m.
  • Effect of Linaclotide on Quality of Life in Adults with Chronic Constipation: Results from a Phase 2b Study, an oral presentation by Bernard Lavins, M.D. on Monday, June 1 at 2:15 p.m.
  • Time to Onset of Linaclotide Effect on the Bowel Habits in Patients with Chronic Constipation: Results from a Phase 2b Study, a poster presentation by
    '/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Video: NASONEX(R) (Mometasone Furoate Monohydrate) Nasal Spray, 50 mcg* Teams Up With American Forests to Educate Nasal Allergy Sufferers and Help Improve Air Quality
2. Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorneys Office Investigation
3. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
5. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
6. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
7. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
8. Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video
9. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
10. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
11. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Paul, MN (PRWEB) September 02, 2014 ... been refined and specially formulated, while preserving the foundation ... solutions for hair loss and scalp problems. There is ... on the market today. , Hair loss is a ... ages. Until now, options for treatment have been limited ...
(Date:9/2/2014)... YOUNGSTOWN, Ohio (PRWEB) September 02, 2014 Humility ... at Home, Sept. 18 at St. Elizabeth Health Center, 1044 ... that provides information about more than 200 common health problems ... family, preventing illness and injury, and advice on when to ... 11 a.m. to noon in the Youngstown Room; the evening ...
(Date:9/2/2014)... announce that the following papers will be published ... 2014, taking place in Barcelona, Spain, 30 August ... biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting ... single-blind, non-inferiority trial, Windecker et al , ... polymer, and drug release have improved clinical outcomes ...
(Date:9/2/2014)... Researchers in New Delhi, India have published a paper on ... asbestos-contaminated work clothes for just 3 months as a child. ... a new article. Click here to read it now. ... patient was diagnosed with mesothelioma after complaining of ... come in contact with her miner father’s dirty work clothes ...
(Date:9/2/2014)... Headaches, both chronic and acute ruin lives. They can ... friends, sleeping and just coping well with daily activities. ... worldwide. The medications prescribed for these conditions frequently don’t ... cases of headache and back pain are of a mechanical ... detect and fix the cause. , When a sports ...
Breaking Medicine News(10 mins):Health News:New All Natural, Organic Hair Recovery Products by Moroccan Eco-Biologics, Restore Lost Hair with No Side Effects 2Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:The Lancet: European Society of Cardiology Congress 2014 media alert 2Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Physical Therapists in Houston Learn Pain Relief Techniques 2
... 13 Ruth W. Messinger, president of American ... today calling on the international community to actively ... into Darfur so workers can continue providing critical ... displaced persons throughout Darfur and Chad."The already fragile ...
... earning the doctor of optometry degree are encouraged to attend the ... and the N.C. State Education Assistance Authority. Conferences are scheduled ... East ... 10:00 a.m. - 12:00 noon, Tuesday, March 24, 2009 in the ...
... 20th Annual AIDS Walk Houston for Living Positive By DesignHOUSTON, ... series "Project Runway," is visiting Houston for the 20th Annual ... his national HIV and AIDS education initiative. On Sunday, ... helps to support more than 100,000 people with HIV and ...
... million gift for its campaign to build a children,s, ... Mission Bay campus, near downtown San Francisco. This is ... hospital fundraising campaign and among the largest gifts in ... percent match to encourage support from other philanthropists, was ...
... Clinical Care Options (CCO), a leader in education ... information provider, have been named the official providers of ... AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention ... 2009, and the XVIII International AIDS Conference in Vienna, ...
... shift to web news -LITTLE FALLS, N.J., March 13 ... reports on the closing and downsizing of many U.S. ... its list of 10 major daily papers most likely to fold ... New York Times reports that three papers ...
Cached Medicine News:Health News:Optometry Career Conferences Set for Five N.C. Campuses in March 2Health News:'Project Runway' Designer in Houston to Educate About Living With HIV and Combat Stigma Associated With the Disease 2Health News:'Project Runway' Designer in Houston to Educate About Living With HIV and Combat Stigma Associated With the Disease 3Health News:UCSF Medical Center receives $125 million gift to build new hospital 2Health News:UCSF Medical Center receives $125 million gift to build new hospital 3Health News:UCSF Medical Center receives $125 million gift to build new hospital 4Health News:Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings 2Health News:Clinical Care Options and NAM Selected by the International AIDS Society to Collaborate on Official Online Conference Coverage From Annual Meetings 3Health News:Print Media Under Siege - Are Readers Disappearing? 2
(Date:9/2/2014)... 2014  Boston Scientific Corporation (NYSE: ... to purchase the Interventional business of Bayer AG. ... to offer physicians and healthcare systems a more ... conditions. The addition of the Bayer ... the Boston Scientific strategy to provide a comprehensive ...
(Date:9/2/2014)... , Sept. 2, 2014  Based on its ... device market, Frost & Sullivan recognizes Novian Health, ... Sullivan Award for Technology Innovation Leadership. Novian Health ... and malignant tumors with its proprietary technology, Novilase ... a reliable, accurate, and easy-to-control ultrasound-guided thermo ablation ...
(Date:9/2/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... consumables to the medical, research and veterinary markets, announced ... Executive Officer, will present at the Morgan Stanley Global ... a.m. ET. The conference will be held at the ... City . About Abaxis Abaxis develops, ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2
... ABBOTT PARK, Ill., April 21 Abbott (NYSE: ... strengthening its pharmaceutical pipeline in immunology and oncology. , ... The acquisition provides Abbott with ... that complement its existing diverse oncology program.  The new Abbott compounds ...
... Magellan Biosciences, Inc., an emerging leader in clinical ... first to offer minocycline and telavancin on IVD-labeled microbroth ... (FDA) has cleared TREK-brand Sensititre MIC plates for testing ... as well as telavancin against Gram positive bacterial isolates ...
Cached Medicine Technology:Abbott Completes Acquisition of Facet Biotech 2FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 2FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 3FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 4
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers....
Medicine Products: